StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Equities researchers at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $20.00 target price on shares of Bio-Path in a research note on Monday, July 8th.

Bio-Path Stock Performance

Shares of Bio-Path stock opened at $1.07 on Wednesday. Bio-Path has a 1 year low of $0.85 and a 1 year high of $14.42. The business has a 50 day moving average price of $1.05 and a 200 day moving average price of $1.84.

Bio-Path (NASDAQ:BPTH) last released its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the firm earned ($10.60) earnings per share. On average, analysts anticipate that Bio-Path will post -6.2 EPS for the current year.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.